Provided by Tiger Fintech (Singapore) Pte. Ltd.

Corvus Pharmaceuticals

3.62
+0.12003.43%
Pre-market: 3.56-0.0600-1.66%08:00 EDT
Volume:1.16M
Turnover:4.17M
Market Cap:246.65M
PE:-3.54
High:3.69
Open:3.50
Low:3.41
Close:3.50
Loading ...

Corvus Pharmaceuticals announces preclinical dataon soquelitinib

TIPRANKS
·
14 Nov 2024

Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis

GlobeNewswire
·
14 Nov 2024

An Intrinsic Calculation For Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Suggests It's 41% Undervalued

Simply Wall St.
·
14 Nov 2024

Corvus Pharmaceuticals Inc : Jefferies Raises Target Price to $13 From $8

THOMSON REUTERS
·
14 Nov 2024

Jefferies Raises Corvus Pharmaceuticals Price Target to $13 From $8, Maintains Buy Rating

MT Newswires Live
·
14 Nov 2024

Oppenheimer Adjusts Corvus Pharmaceuticals Price Target to $14 From $8, Maintains Outperform Rating

MT Newswires Live
·
13 Nov 2024

Corvus Pharmaceuticals price target raised to $24 from $21 at Ladenburg

TIPRANKS
·
13 Nov 2024

Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ...

GuruFocus.com
·
13 Nov 2024

Corvus Pharmaceuticals Inc reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
13 Nov 2024

Corvus Pharma Q3 2024 GAAP EPS $(0.60) Misses $(0.11) Estimate

Benzinga
·
13 Nov 2024

Corvus: Q3 Earnings Snapshot

Associated Press Finance
·
13 Nov 2024

Corvus Pharmaceuticals options imply 17.7% move in share price post-earnings

TIPRANKS
·
13 Nov 2024

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

THOMSON REUTERS
·
10 Nov 2024

Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer

GlobeNewswire
·
10 Nov 2024

Corvus Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
09 Nov 2024

Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024

GlobeNewswire
·
06 Nov 2024

Corvus Pharmaceuticals options imply 12.0% move in share price post-earnings

TIPRANKS
·
06 Nov 2024

Corvus Pharmaceuticals Inc expected to post a loss of 11 cents a share - Earnings Preview

Reuters
·
02 Nov 2024